In this study, gefitinib‐resistant cells showed diverse CIS, TMB, and MATH scores compared with dacomitinib‐induced resistant cells, suggesting that the wide range of inhibitory activity of dacomitinib might prevent gene alterations and yield a low proportion of sub‐clones with EGFR‐T790M mutation.23 This evidence concerns the gene EGFR and in situ carcinoma.